drugset
drugset / Trial / NCT05357573

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

NCT05357573 ↗

Phase 4 Completed 9 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with TIO

Timeline

Start
2022-09-07
Primary completion
2023-11-22
Completion
2023-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Burosumab Monoclonal antibody 0.3 mg/kg Subcutaneous
Subject Burosumab Monoclonal antibody 0.6 mg/kg Subcutaneous
Subject Burosumab Monoclonal antibody 1 mg/kg Subcutaneous
Subject Burosumab Monoclonal antibody 1.4 mg/kg Subcutaneous
Subject Burosumab Monoclonal antibody 2 mg/kg Subcutaneous

Indications

Oncogenic osteomalacia